Angioplasty -- New Application For Progen Drugs.BRISBANE, Australia--(BW HealthWire)--April 7, 1999-- Research Team Demonstrates the Ability to Prevent Thickening of Damaged Cartoid Artery by Up to 45% Using Progen's Novel Heparanase Inhibitor, a Carbohydrate Based Molecule Progen Industries Ltd. (Nasdaq:PGLAF PGLAF Project Gutenberg Literary Archive Foundation )(ASX ASX See: Australian Stock Exchange :PGL Persistent generalized lymphadenopathy (PGL) A condition in which HIV continues to produce chronic painless swellings in the lymph nodes during the latency period. Mentioned in: AIDS ) reported today that preliminary studies conducted at the University of Queensland The University of Queensland (UQ) is the longest-established university in the state of Queensland, Australia, a member of Australia's Group of Eight, and the Sandstone Universities. It is also a founding member of the international Universitas 21 organisation. and the John Curtin School of Medical Research The John Curtin School of Medical Research (JCMSR) is a major biomedial research centre in Australia, based at the Australian National University, Canberra. The school was founded in 1948, as a result of the vision of Australian Nobel Laureate Sir Howard Florey and Prime Minister , Canberra, show that Progen's novel heparanase inhibitor, when used in experimental models that mimic vascular damage associated with angioplasty, significantly moderates the narrowing of the coronary artery. The Progen funded research team at the University of Queensland have demonstrated in preliminary studies that Progen's novel heparanase inhibitor, a carbohydrate based molecule, can reduce the thickening of the damaged cartoid artery by up to 45%. In the experimental model of restenosis developed at the University of Queensland, the cartoid artery is damaged and the resulting alteration in the arterial muscle cells resembles that which occurs following angioplasty. On a world-wide basis, over one million angioplasties were performed in 1997 to treat clogged arteries. The surgical procedure involves inflating a small balloon in the patient's coronary artery to open the blockage and restore normal blood flow. Up to 40% of patients undergoing this procedure develop a chronic narrowing of coronary arteries (restenosis). In restenosis the muscle cells lining the blood vessel become altered and cause the entire artery to contract and hence reduce blood flow. When this occurs, the angioplasty has to be repeated or bypass surgery may be performed. This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results as a result of certain risks and uncertainties, including but not limited to risks associated with the development and manufacture of PI-88 and inherent in the extensive regulatory approval process mandated by the Australian Therapeutic Goods Administration The Therapeutic Goods Administration or TGA is the regulatory body for therapeutic goods (including medicines, medical devices, gene technology, and blood products) in Australia. and the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. , delays in obtaining the necessary approvals for clinical testing and marketing of PI-88, market acceptance of the compounds, general economic conditions, and other risks and uncertainties detailed from time to time in Progen's filings with the Australian Stock Exchange Australian Stock Exchange (ASX) Australia's major securities market, formed when the six state stock exchanges (Adelaide, Brisbane, Hobart, Melbourne, Perth, and Sydney stock exchanges) were merged in 1987. and the United States Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion